NCT04832776View on ClinicalTrials.gov

FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases

PHASE2RecruitingINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

April 17, 2021

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2025

Conditions
Liver Metastasis Colon Cancer
Interventions
DRUG

Cetuximab

one group plus cetuximab

DRUG

Bevacizumab

one group plus bevacizumab

DRUG

FOLFOXIRI

FOLFOXIRI

Trial Locations (1)

200032

RECRUITING

Department of Colorectal Surgery Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER